Preparation and purification methods for mesenchymal stem cell derived secretome
US-2024091268-A1 · Mar 21, 2024 · US
US9993389B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9993389-B2 |
| Application number | US-201214122847-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 19, 2012 |
| Priority date | Sep 19, 2011 |
| Publication date | Jun 12, 2018 |
| Grant date | Jun 12, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Red blood cell products and compositions are disclosed. The product includes a container made from PVC or a non-PVC material that is substantially free of a phthalate plasticizer but otherwise includes one or more non-phthalate plasticizers or extractable agents. The product includes a RBC concentrate which has been combined with an additive solution for storing the RBCs.
Opening claim text (preview).
The invention claimed is: 1. A container for storing red blood cell compositions comprising: one or more container walls defining an interior chamber, said container wall(s) comprising a polymeric material that includes polyvinyl chloride and that is (a) at least substantially free of phthalate and (b) comprises up to approximately 45%, by weight, of two extractable non-phthalate ester plasticizers that are effective in suppressing hemolysis in red blood cells, wherein one of said plasticizers is a citrate ester and the other of said ester plasticizers is 1, 2-cyclohexane dicarboxylic acid diisononyl ester. 2. The container of claim 1 wherein said citrate ester is n-butyryl-tri-n-hexyl-citrate. 3. The container of claim 1 wherein said citrate ester is acetyltri-n-butyl citrate. 4. The container of claim 1 further comprising at least a third agent. 5. The container of claim 4 wherein said third agent is effective in suppressing hemolysis in red blood cells. 6. The container of claim 1 wherein said citrate and 1, 2-cyclohexane dicarboxylic acid diisononyl esters together comprise between 20%-45%, by weight, of said polymeric material. 7. The container of claim 1 wherein one of said citrate and 1, 2-cyclohexane dicarboxylic acid diisononyl esters together comprises between approximately 5%-60%, by weight, of the combined weight of said citrate and 1, 2-cyclohexane dicarboxylic acid diisononyl ester and, optionally, additional agents. 8. The container of claim 1 wherein said polyvinyl chloride comprises at least approximately 55%, by weight, of said polymeric material. 9. The container of claim 1 wherein said polymeric material comprises approximately 60%-70% polyvinyl chloride, approximately 15%-30% 1, 2-cyclohexane dicarboxylic acid diisononyl ester and approximately 5%-15% citrate ester. 10. The container of claim 9 further comprising approximately 4%-10% epoxidized oil. 11. The container of claim 10 further comprising approximately 0.5%-3.0% of additional co-stabilizers and lubricants. 12. The container of claim 9 wherein said citrate ester is n-butyryl-tri-n-hexyl-citrate.
Human Necessities · mapped topic
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Bag-type containers · CPC title
comprising vinyl halide (co)polymers, e.g. PVC, PVDC, PVF, PVDF · CPC title
of synthetic resin · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.